Bio-Thera Solutions Ltd. has signed its first partnership to establish a presence in Russia, agreeing to out-license exclusive rights for its biosimilar Simponi (golimumab) candidate, BAT2506, in Russia and the Commonwealth and Indepdenent States to local player Pharmapark.
The Chinese firm says it is to begin a global Phase III study for BAT2506 in patients with active psoriatic...






